Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 9, 2013, Pages 1962-1970

  Ainai, Akira ^a   Tamura, Shin Ichi ^a   Suzuki, Tadaki ^a   Van Riet, Elly ^a   Ito, Ryo ^a,b   Odagiri, Takato ^a   Tashiro, Masato ^a   Kurata, Takeshi ^a   Hasegawa, Hideki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Haemagglutination inhibiting antibody; Healthy adult volunteer; Influenza virus; Intranasal vaccination; Neutralizing antibody

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CROSS REACTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; INFECTION PREVENTION; INFLUENZA A (H3N2); INFLUENZA VACCINATION; MALE; NORMAL HUMAN; NOSE MUCUS; SERUM; TREATMENT DURATION;

HAEMAGGLUTINATION-INHIBITING ANTIBODY; HEALTHY ADULT VOLUNTEER; INFLUENZA VIRUS; INTRANASAL VACCINATION; NEUTRALIZING ANTIBODY;

ADMINISTRATION, INTRANASAL; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINES; INFLUENZA, HUMAN; NASAL MUCOSA; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE; VACCINATION; VACCINES, INACTIVATED;

EID: 84884612155     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25458     Document Type: Article

References (50)

1. Murphy BR, Webster RG. Orthomyxoviruses. In: Fields BN, Knipe DM, M. HP, Chanock RM, Melnick JL, Monath TP, et al., eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 1996:1397-445.
2. Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 1989; 146:107-16; PMID:2659262; http://dx.doi.org/10.1007/978-3-642-74529-4-12
3. Murphy BR. Mucosal Immunity to Viruses. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGee JR, Bienenstock J, eds. Handbook of Mucosal Immunology. San Diego: Academic Press, 1994:333-43.
4. Tamura S, Funato H, Hirabayashi Y, Kikuta K, Suzuki Y, Nagamine T, et al. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. Vaccine 1990; 8:479-85; PMID:2251874; http://dx.doi.org/10.1016/0264-410X(90)90250-P
5. Tamura S, Funato H, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, et al. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur J Immunol 1991; 21:1337-44; PMID:1646112; http://dx.doi.org/10.1002/eji.1830210602
6. Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 2002; 168:2930-8; PMID:11884464
7. Asahi-Ozaki Y, Yoshikawa T, Iwakura Y, Suzuki Y, Tamura S, Kurata T, et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol 2004; 74:328-35; PMID:15332283; http://dx.doi.org/10.1002/jmv.20173
8. Ito R, Ozaki YA, Yoshikawa T, Hasegawa H, Sato Y, Suzuki Y, et al. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 2003; 21:2362-71; PMID:12744867; http://dx.doi.org/10.1016/S0264- 410X(03)00078-1
9. Renegar KB, Small PA Jr., Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004; 173:1978-86; PMID:15265932
10. Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 2004; 57:236-47; PMID:15623947
11. Jodar L, Duclos P, Milstien JB, Griffiths E, Aguado MT, Clements CJ. Ensuring vaccine safety in immunization programmes-A WHO perspective. Vaccine 2001; 19:1594-605; PMID:11166881; http://dx.doi.org/10.1016/S0264-410X(00)00358- 3
12. Kuno-Sakai H, Kimura M, Ohta K, Shimojima R, Oh Y, Fukumi H. Developments in mucosal influenza virus vaccines. Vaccine 1994; 12:1303-10; PMID:7856295; http://dx.doi.org/10.1016/S0264-410X(94)80056-6
13. Hashigucci K, Ogawa H, Ishidate T, Yamashita R, Kamiya H, Watanabe K, et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 1996; 14:113-9; PMID:8852406; http://dx.doi.org/10.1016/0264-410X(95)00174-Y
14. Muszkat M, Yehuda AB, Schein MH, Friedlander Y, Naveh P, Greenbaum E, et al. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J Med Virol 2000; 61:100-6; PMID:10745240; http://dx.doi.org/10.1002/(SICI)1096- 9071(200005)61:1;100::AIDJMV16;
15. Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, et al. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine 2002; 20:1232-9; PMID:11803086; http://dx.doi.org/10.1016/ S0264-410X(01)00396-6
16. Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine 2004; 22:2566-77; PMID:15193382; http://dx.doi.org/10.1016/j.vaccine.2003.12.018
17. Durrer P, Glück U, Spyr C, Lang AB, Zurbriggen R, Herzog C, et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 2003; 21:4328-34; PMID:14505915; http://dx.doi.org/10.1016/S0264- 410X(03)00457-2
18. Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, et al. Intranasal administration of a proteosome-influenza vaccine is well-Tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006; 24:254-62; PMID:16129526; http://dx.doi.org/10.1016/j. vaccine.2005.07.088
19. Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, Couch RB. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 2007; 25:5367-73; PMID:17559990; http://dx.doi.org/10.1016/j.vaccine.2007.05.002
20. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 2005; 79:2910-9; PMID:15709010; http://dx.doi.org/10.1128/JVI.79.5.2910-2919.2005
21. Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 2007; 196:1313-20; PMID:17922395; http://dx.doi.org/10.1086/521304
22. European Medicines Agency. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). In: (CPMP) CfPMP, ed. London: Committee for Proprietary Medical Products (CPMP), 1997.
23. U.S. Food and Drug Administration. Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. In: Services USDoHaH, ed., 2007.
24. European Medicines Agency. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorization application (CPMP/VFG/4717/03-Rev.1). In: (CHMP) CfMPfHU, ed. London: Committee for Medicinal Products for Human Use (CHMP), 2008.
25. Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother 2013; 9: In press; PMID:23291930; http://dx.doi.org/10.4161/hv.22908.
26. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005; 58:195-207; PMID:16116250
27. Tamura S. Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine 2010; 28:6393-7; PMID:20493820; http://dx.doi.org/10.1016/j. vaccine.2010.05.019
28. Okuno Y, Tanaka K, Baba K, Maeda A, Kunita N, Ueda S. Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 1990; 28:1308-13; PMID:2380359
29. Lu BL, Webster RG, Hinshaw VS. Failure to detect hemagglutination- inhibiting antibodies with intact avian influenza virions. Infect Immun 1982; 38:530-5; PMID:6292104
30. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43; PMID:10074505
31. Ainai A, Tamura S, Suzuki T, Ito R, Asanuma H, Tanimoto T, et al. Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine. J Med Virol 2012; 84:336-44; PMID:22170556; http://dx.doi.org/10.1002/jmv.22273
32. Kurono Y, Mogi G. Secretory IgA and serum type IgA in nasal secretion and antibody activity against the M protein. Ann Otol Rhinol Laryngol 1987; 96:419-24; PMID:3304089
33. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 2003; 21:3212-8; PMID:12804850; http://dx.doi.org/10.1016/S0264-410X(03)00234-2
34. Tamura S, Hasegawa H, Kurata T. Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments. Jpn J Infect Dis 2010; 63:8-15; PMID:20093755
35. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004; 101:5598-603; PMID:15034168; http://dx.doi.org/10.1073/ pnas.0400937101
36. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-31; PMID:14976261; http://dx.doi.org/10.1126/science.1093616
37. Kang SM, Guo L, Yao Q, Skountzou I, Compans RW. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J Virol 2004; 78:9624-32; PMID:15331695; http://dx.doi.org/10.1128/JVI.78.18.9624-9632.2004
38. Koyama S, Aoshi T, Tanimoto T, Kumagai Y, Kobiyama K, Tougan T, et al. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2010; 2:25ra24; PMID:20424013; http://dx.doi.org/10. 1126/scitranslmed.3000759
39. Clements ML, Betts RF, Tierney EL, Murphy BR. Resistance of adults to challenge with influenza A wildtype virus after receiving live or inactivated virus vaccine.J Clin Microbiol 1986; 23:73-6; PMID:3700611
40. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-Type virus. J Clin Microbiol 1986; 24:157-60; PMID:3722363
41. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, et al. Correlates of immune protection induced by live, attenuated, cold-Adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133-7; PMID:10720541; http://dx.doi.org/10.1086/315323
42. Murphy BR, Phelan MA, Nelson DL, Yarchoan R, Tierney EL, Alling DW, et al. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol 1981; 13:554-60; PMID:7240388
43. Takahashi Y, Hasegawa H, Hara Y, Ato M, Ninomiya A, Takagi H, et al. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J Infect Dis 2009; 199:1629-37; PMID:19385735; http://dx.doi.org/10.1086/598954
44. Hirota Y, Kaji M, Ide S, Goto S, Oka T. The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age. Vaccine 1996; 14:1597-602; PMID:9032887; http://dx.doi.org/10.1016/S0264- 410X(96)00153-3
45. Tobita K, Sugiura A, Enomote C, Furuyama M. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol 1975; 162:9-14; PMID:1214709; http://dx.doi.org/10.1007/BF02123572
46. Kadowaki S, Chen Z, Asanuma H, Aizawa C, Kurata T, Tamura S. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. Vaccine 2000; 18:2779-88; PMID:10812219; http://dx.doi.org/10.1016/S0264-410X(00)00087-6
47. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoint. Am J Hyg 1938; 27:493-7
48. Davenport FM, Hennessy AV, Brandon FM, Webster RG, Barrett CD Jr., Lease GO. Comparisons of Serologic and Febrile Responses in Humans to Vaccination with Influenza a Viruses or Their Hemagglutinins. J Lab Clin Med 1964; 63:5-13; PMID:14102904
49. Hierholzer JC, Suggs MT, Hall EC. Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation. Appl Microbiol 1969; 18:824-33; PMID:4984203
50. Phelan MA, Mayner RE, Bucher DJ, Ennis FA. Purification of influenza virus glycoproteins for the preparation and standardization of immunological potency testing reagents. J Biol Stand 1980; 8:233-42; PMID:7410447; http://dx.doi.org/10.1016/S0092-1157(80)80039-4